Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SP

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 23, 2023 8:10pm

185 Views

Post# 35357673

RE:RE:RE:SP

No lonc17 that is not enough. I certaintly don't recall any of those trials being registered as clinical trials other than the head and neck trial that had been run in Russia. Blame Brad Thompson for that one. So since you've been quite adamant in your criticism of ONCY, I ask that you to post the clinical trial numbers found at clinical.trials.gov, so that we can accurately judge your veracity on this matter.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas